Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?
The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012. 1,2 Most patients with NETs are diagnosed with metastatic disease, at which point curative surgery is no lon...
Gespeichert in:
| Veröffentlicht in: | Oncology (Williston Park, N.Y.) N.Y.), 2024-11, Vol.38 (11), p.442-443 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 443 |
|---|---|
| container_issue | 11 |
| container_start_page | 442 |
| container_title | Oncology (Williston Park, N.Y.) |
| container_volume | 38 |
| creator | Bahri, Natasha Crook, Christiana Daneng Li Md |
| description | The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012. 1,2 Most patients with NETs are diagnosed with metastatic disease, at which point curative surgery is no longer a treatment option. 3 Prior to 2017, available treatments for advanced NETs included somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin]), targeted therapy (everolimus [Afinitor] and sunitinib [Sutent]), and chemotherapy. 4-7 In 2017, the World Health Organization added a classification for well-differentiated grade 3 NETs (Ki67 > 20% and ≤ 55%). 8 Previously these tumors were placed under the umbrella of poorly differentiated neuroendocrine carcinomas. Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined. |
| doi_str_mv | 10.46883/2024.25921029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3131848101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3131848101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c208t-b6cf4cddf1254f653988276af2f7ad236c22a308596a618baa2f3865032a9ce43</originalsourceid><addsrcrecordid>eNpdkD1PwzAQhj2AaCmsjMgSC0vK2Y4dmwWhUqCooktQx8hNbJoqH8V2Bv49KW0Z0A23PO-ruwehKwLjWEjJ7ijQeEy5ogSoOkFDkAoiBYoM0Ln3GwAqBMgzNGCKJ5CAHKK3ifahbD6xxsuyMPh9mt7j5do0eOZxWBu82Iay1hVOy9pg2zpMkmTeRU9t0P0YnDqjQ22a8HCBTq2uvLk87BH6eJ6mk9dovniZTR7nUU5BhmglchvnRWEJ5bEVnCkpaSK0pTbRBWUip1QzkFwJLYhcaU0tk4IDo1rlJmYjdLvv3br2qzM-ZHXpc1NVujFt5zNGGJGxJEB69OYfumk71_TX9RRNOAPGd9R4T-Wu9d4Zm21d_7P7zghkv2azndnsaLYPXB9qu1Vtij_8qJX9AFl2cRY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3127530351</pqid></control><display><type>article</type><title>Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Bahri, Natasha ; Crook, Christiana ; Daneng Li Md</creator><creatorcontrib>Bahri, Natasha ; Crook, Christiana ; Daneng Li Md</creatorcontrib><description>The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012. 1,2 Most patients with NETs are diagnosed with metastatic disease, at which point curative surgery is no longer a treatment option. 3 Prior to 2017, available treatments for advanced NETs included somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin]), targeted therapy (everolimus [Afinitor] and sunitinib [Sutent]), and chemotherapy. 4-7 In 2017, the World Health Organization added a classification for well-differentiated grade 3 NETs (Ki67 > 20% and ≤ 55%). 8 Previously these tumors were placed under the umbrella of poorly differentiated neuroendocrine carcinomas. Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.</description><identifier>ISSN: 0890-9091</identifier><identifier>DOI: 10.46883/2024.25921029</identifier><identifier>PMID: 39570708</identifier><language>eng</language><publisher>United States: MultiMedia Healthcare Inc</publisher><subject>Cancer therapies ; Epidemiology ; Humans ; Leukemia ; Medical prognosis ; Metastasis ; Neuroendocrine tumors ; Neuroendocrine Tumors - pathology ; Neuroendocrine Tumors - radiotherapy ; Neuroendocrine Tumors - therapy ; Octreotide - analogs & derivatives ; Octreotide - therapeutic use ; Organometallic Compounds - therapeutic use ; Patients</subject><ispartof>Oncology (Williston Park, N.Y.), 2024-11, Vol.38 (11), p.442-443</ispartof><rights>Copyright MultiMedia Healthcare Inc. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39570708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bahri, Natasha</creatorcontrib><creatorcontrib>Crook, Christiana</creatorcontrib><creatorcontrib>Daneng Li Md</creatorcontrib><title>Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?</title><title>Oncology (Williston Park, N.Y.)</title><addtitle>Oncology (Williston Park)</addtitle><description>The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012. 1,2 Most patients with NETs are diagnosed with metastatic disease, at which point curative surgery is no longer a treatment option. 3 Prior to 2017, available treatments for advanced NETs included somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin]), targeted therapy (everolimus [Afinitor] and sunitinib [Sutent]), and chemotherapy. 4-7 In 2017, the World Health Organization added a classification for well-differentiated grade 3 NETs (Ki67 > 20% and ≤ 55%). 8 Previously these tumors were placed under the umbrella of poorly differentiated neuroendocrine carcinomas. Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.</description><subject>Cancer therapies</subject><subject>Epidemiology</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Neuroendocrine Tumors - radiotherapy</subject><subject>Neuroendocrine Tumors - therapy</subject><subject>Octreotide - analogs & derivatives</subject><subject>Octreotide - therapeutic use</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Patients</subject><issn>0890-9091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkD1PwzAQhj2AaCmsjMgSC0vK2Y4dmwWhUqCooktQx8hNbJoqH8V2Bv49KW0Z0A23PO-ruwehKwLjWEjJ7ijQeEy5ogSoOkFDkAoiBYoM0Ln3GwAqBMgzNGCKJ5CAHKK3ifahbD6xxsuyMPh9mt7j5do0eOZxWBu82Iay1hVOy9pg2zpMkmTeRU9t0P0YnDqjQ22a8HCBTq2uvLk87BH6eJ6mk9dovniZTR7nUU5BhmglchvnRWEJ5bEVnCkpaSK0pTbRBWUip1QzkFwJLYhcaU0tk4IDo1rlJmYjdLvv3br2qzM-ZHXpc1NVujFt5zNGGJGxJEB69OYfumk71_TX9RRNOAPGd9R4T-Wu9d4Zm21d_7P7zghkv2azndnsaLYPXB9qu1Vtij_8qJX9AFl2cRY</recordid><startdate>20241105</startdate><enddate>20241105</enddate><creator>Bahri, Natasha</creator><creator>Crook, Christiana</creator><creator>Daneng Li Md</creator><general>MultiMedia Healthcare Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20241105</creationdate><title>Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?</title><author>Bahri, Natasha ; Crook, Christiana ; Daneng Li Md</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c208t-b6cf4cddf1254f653988276af2f7ad236c22a308596a618baa2f3865032a9ce43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer therapies</topic><topic>Epidemiology</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Neuroendocrine Tumors - radiotherapy</topic><topic>Neuroendocrine Tumors - therapy</topic><topic>Octreotide - analogs & derivatives</topic><topic>Octreotide - therapeutic use</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bahri, Natasha</creatorcontrib><creatorcontrib>Crook, Christiana</creatorcontrib><creatorcontrib>Daneng Li Md</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology (Williston Park, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bahri, Natasha</au><au>Crook, Christiana</au><au>Daneng Li Md</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?</atitle><jtitle>Oncology (Williston Park, N.Y.)</jtitle><addtitle>Oncology (Williston Park)</addtitle><date>2024-11-05</date><risdate>2024</risdate><volume>38</volume><issue>11</issue><spage>442</spage><epage>443</epage><pages>442-443</pages><issn>0890-9091</issn><abstract>The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012. 1,2 Most patients with NETs are diagnosed with metastatic disease, at which point curative surgery is no longer a treatment option. 3 Prior to 2017, available treatments for advanced NETs included somatostatin analogues (lanreotide [Somatuline] and octreotide [Sandostatin]), targeted therapy (everolimus [Afinitor] and sunitinib [Sutent]), and chemotherapy. 4-7 In 2017, the World Health Organization added a classification for well-differentiated grade 3 NETs (Ki67 > 20% and ≤ 55%). 8 Previously these tumors were placed under the umbrella of poorly differentiated neuroendocrine carcinomas. Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.</abstract><cop>United States</cop><pub>MultiMedia Healthcare Inc</pub><pmid>39570708</pmid><doi>10.46883/2024.25921029</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-9091 |
| ispartof | Oncology (Williston Park, N.Y.), 2024-11, Vol.38 (11), p.442-443 |
| issn | 0890-9091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3131848101 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Cancer therapies Epidemiology Humans Leukemia Medical prognosis Metastasis Neuroendocrine tumors Neuroendocrine Tumors - pathology Neuroendocrine Tumors - radiotherapy Neuroendocrine Tumors - therapy Octreotide - analogs & derivatives Octreotide - therapeutic use Organometallic Compounds - therapeutic use Patients |
| title | Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T15%3A31%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Casting%20a%20Wide%20NET:%20When%20Is%20the%20Optimal%20Time%20for%20177Lu-Dotatate%20Treatment?&rft.jtitle=Oncology%20(Williston%20Park,%20N.Y.)&rft.au=Bahri,%20Natasha&rft.date=2024-11-05&rft.volume=38&rft.issue=11&rft.spage=442&rft.epage=443&rft.pages=442-443&rft.issn=0890-9091&rft_id=info:doi/10.46883/2024.25921029&rft_dat=%3Cproquest_cross%3E3131848101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3127530351&rft_id=info:pmid/39570708&rfr_iscdi=true |